bluuebunny/crossref_metadata_2025 huggingface dataset:
Data from Chemotherapy and Thyroid Cancer Risk: A Report from the Childhood Cancer Survivor Study
Authors: Veiga Lene H.S. , Bhatti Parveen , Ronckers Cécile M. , Sigurdson Alice J. , Stovall Marilyn , Smith Susan A. , Weathers Rita , Leisenring Wendy , Mertens Ann C. , Hammond Sue , Neglia Joseph P. , Meadows Anna T. , Donaldson Sarah S. , Sklar Charles A. , Friedman Debra L. , Robison Leslie L. , Inskip Peter D.
Published: April 2023

Abstract
Background: Although ionizing radiation is an established environmental risk factor for thyroid cancer, the effect of chemotherapy drugs on thyroid cancer risk remains unclear. We evaluated the chemotherapy-related risk of thyroid cancer in childhood cancer survivors and the possible joint effects of chemotherapy and radiotherapy.

Methods: The study included 12,547 five-year survivors of childhood cancer diagnosed during 1970 through 1986. Chemotherapy and radiotherapy information was obtained from medical records, and radiation dose was estimated to the thyroid gland. Cumulative incidence and relative risks were calculated with life-table methods and Poisson regression. Chemotherapy-related risks were evaluated separately by categories of radiation dose.

Results: Histologically confirmed thyroid cancer occurred in 119 patients. Thirty years after the first childhood cancer treatment, the cumulative incidence of thyroid cancer was 1.3% (95% CI, 1.0–1.6) for females and 0.6% (0.4–0.8) for males. Among patients with thyroid radiation doses of 20 Gy or less, treatment with alkylating agents was associated with a significant 2.4-fold increased risk of thyroid cancer (95% CI, 1.3–4.5; P = 0.002). Chemotherapy risks decreased as radiation dose increased, with a significant decrease for patients treated with alkylating agents (Ptrend = 0.03). No chemotherapy-related risk was evident for thyroid radiation doses more than 20 Gy.

Conclusions: Treatments with alkylating agents increased thyroid cancer risk, but only in the radiation dose range less than 20 Gy, in which cell sparing likely predominates over cell killing.

Impact: Our study adds to the evidence for chemotherapy agent–specific increased risks of thyroid cancer, which to date, were mainly thought to be related to prior radiotherapy. Cancer Epidemiol Biomarkers Prev; 21(1); 92–101. ©2011 AACR.
Data from Measured Adiposity in Relation to Head and Neck Cancer Risk in the European Prospective Investigation into Cancer and Nutrition
Authors: Ward Heather A. , Wark Petra A. , Muller David C. , Steffen Annika , Johansson Mattias , Norat Teresa , Gunter Marc J. , Overvad Kim , Dahm Christina C. , Halkjær Jytte , Tjønneland Anne , Boutron-Ruault Marie-Christine , Fagherazzi Guy , Mesrine Sylvie , Brennan Paul , Freisling Heinz , Li Kuanrong , Kaaks Rudolf , Trichopoulou Antonia , Lagiou Pagona , Panico Salavatore , Grioni Sara , Tumino Rosario , Vineis Paolo , Palli Domenico , Peeters Petra H.M. , Bueno-de-Mesquita H. Bas. , Weiderpass Elisabete , Agudo Antonio , Quirós Jose Ramón , Larrañaga Nerea , Ardanaz Eva , Huerta José María , Sánchez María-José , Laurell Göran , Johansson Ingegerd , Westin Ulla , Wallström Peter , Bradbury Kathryn E. , Wareham Nicholas J. , Khaw Kay-Tee , Pearson Clare , Boeing Heiner , Riboli Elio
Published: April 2023

Abstract
Background: Emerging evidence from cohort studies indicates that adiposity is associated with greater incidence of head and neck cancer. However, most studies have used self-reported anthropometry which is prone to error.

Methods: Among 363,094 participants in the European Prospective Investigation into Cancer and Nutrition study (EPIC) with measured anthropometry, there were 837 incident cases of head and neck cancer. Head and neck cancer risk was examined in relation to body mass index (BMI) [lean: <22.5 kg/m2, normal weight (reference): 22.5–24.9 kg/m2, overweight 25–29.9 kg/m2, obese: ≥30 kg/m2], waist circumference (WC), hip circumference (HC), and waist-to-hip ratio (WHR) using Cox proportional hazards models.

Results: Among men, a BMI < 22.5 kg/m2 was associated with higher head and neck cancer risk [HR 1.62; 95% confidence interval (CI), 1.23–2.12)]; BMI was not associated with head and neck cancer among women. WC and WHR were associated with greater risk of head and neck cancer among women (WC per 5 cm: HR, 1.08; 95% CI, 1.02–1.15; WHR per 0.1 unit: HR, 1.64; 95% CI, 1.38–1.93). After stratification by smoking status, the association for WHR was present only among smokers (Pinteraction = 0.004). Among men, WC and WHR were associated with head and neck cancer only upon additional adjustment for BMI (WC per 5 cm: HR 1.16; 95% CI, 1.07–1.26; WHR per 0.1 unit: HR, 1.42; 95% CI, 1.21–1.65).

Conclusions: Central adiposity, particularly among women, may have a stronger association with head and neck cancer risk than previously estimated.

Impact: Strategies to reduce obesity may beneficially impact head and neck cancer incidence. Cancer Epidemiol Biomarkers Prev; 26(6); 895–904. ©2017 AACR.
Data from The Role of Stage at Diagnosis in Colorectal Cancer Black–White Survival Disparities: A Counterfactual Causal Inference Approach
Authors: Valeri Linda , Chen Jarvis T. , Garcia-Albeniz Xabier , Krieger Nancy , VanderWeele Tyler J. , Coull Brent A.
Published: April 2023

Abstract
Background: To date, a counterfactual framework has not been used to study determinants of social inequalities in cancer. Considering the case of colorectal cancer, for which racial/ethnic differences in stage at diagnosis and survival are well documented, we quantify the extent to which black versus white survival disparities would be reduced had disparities in stage at diagnosis been eliminated in a large patient population.

Methods: We obtained data on colorectal cancer patients (diagnosed between 1992 and 2005 and followed until 2010) from US-SEER (Surveillance, Epidemiology, and End Results) cancer registries. We employed a counterfactual approach to estimate the mean survival time up to the 60th month since diagnosis for black colorectal cancer patients had black–white disparities in stage at diagnosis been eliminated.

Results: Black patients survive approximately 4.0 [confidence interval (CI), 4.6–3.2] months less than white patients within five years since diagnosis. Had disparities in stage at diagnosis been eliminated, survival disparities decrease to 2.6 (CI, 3.4–1.7) months, an approximately 35% reduction. For patients diagnosed after the age of 65 years, disparities would be halved, while reduction of approximately 30% is estimated for younger patients. Survival disparities would be reduced by approximately 44% for women and approximately 26% for men.

Conclusions: Employing a counterfactual approach and allowing for heterogeneities in black–white disparities across patients' characteristics, we give robust evidence that elimination of disparities in stage at diagnosis contributes to a substantial reduction in survival disparities in colorectal cancer.

Impact: We provide the first evidence in the SEER population that elimination of inequities in stage at diagnosis might lead to larger reductions in survival disparities among elderly and women. Cancer Epidemiol Biomarkers Prev; 25(1); 83–89. ©2015 AACR.
Data from Gene Set Analysis of Survival Following Ovarian Cancer Implicates Macrolide Binding and Intracellular Signaling Genes
Authors: Fridley Brooke L. , Jenkins Gregory D. , Tsai Ya-Yu , Song Honglin , Bolton Kelly L. , Fenstermacher David , Tyrer Jonathan , Ramus Susan J. , Cunningham Julie M. , Vierkant Robert A. , Chen Zhihua , Chen Y. Ann , Iversen Ed , Menon Usha , Gentry-Maharaj Aleksandra , Schildkraut Joellen , Sutphen Rebecca , Gayther Simon A. , Hartmann Lynn C. , Pharoah Paul D.P. , Sellers Thomas A. , Goode Ellen L.
Published: April 2023

Abstract
Background: Genome-wide association studies (GWAS) for epithelial ovarian cancer (EOC), the most lethal gynecologic malignancy, have identified novel susceptibility loci. GWAS for survival after EOC have had more limited success. The association of each single-nucleotide polymorphism (SNP) individually may not be well suited to detect small effects of multiple SNPs, such as those operating within the same biologic pathway. Gene set analysis (GSA) overcomes this limitation by assessing overall evidence for association of a phenotype with all measured variation in a set of genes.

Methods: To determine gene sets associated with EOC overall survival, we conducted GSA using data from two large GWAS (N cases = 2,813, N deaths = 1,116), with a novel Principal Component-Gamma GSA method. Analysis was completed for all cases and then separately for high-grade serous histologic subtype.

Results: Analysis of the high-grade serous subjects resulted in 43 gene sets with P < 0.005 (1.7%); of these, 21 gene sets had P < 0.10 in both GWAS, including intracellular signaling pathway (P = 7.3 × 10−5) and macrolide binding (P = 6.2 × 10−4) gene sets. The top gene sets in analysis of all cases were meiotic mismatch repair (P = 6.3 × 10−4) and macrolide binding (P = 1.0 × 10−3). Of 18 gene sets with P < 0.005 (0.7%), eight had P < 0.10 in both GWAS.

Conclusion: This research detected novel gene sets associated with EOC survival.

Impact: Novel gene sets associated with EOC survival might lead to new insights and avenues for development of novel therapies for EOC and pharmacogenomic studies. Cancer Epidemiol Biomarkers Prev; 21(3); 529–36. ©2012 AACR.
Data from Use of a Urinary Sugars Biomarker to Assess Measurement Error in Self-Reported Sugars Intake in the Nutrition and Physical Activity Assessment Study (NPAAS)
Authors: Tasevska Natasha , Midthune Douglas , Tinker Lesley F. , Potischman Nancy , Lampe Johanna W. , Neuhouser Marian L. , Beasley Jeannette M. , Van Horn Linda , Prentice Ross L. , Kipnis Victor
Published: April 2023

Abstract
Background: Measurement error in self-reported sugars intake may be obscuring the association between sugars and cancer risk in nutritional epidemiologic studies.

Methods: We used 24-hour urinary sucrose and fructose as a predictive biomarker for total sugars, to assess measurement error in self-reported sugars intake. The Nutrition and Physical Activity Assessment Study (NPAAS) is a biomarker study within the Women's Health Initiative (WHI) Observational Study that includes 450 postmenopausal women ages 60 to 91 years. Food Frequency Questionnaires (FFQ), four-day food records (4DFR), and three 24-hour dietary recalls (24HRs) were collected along with sugars and energy dietary biomarkers.

Results: Using the biomarker, we found self-reported sugars to be substantially and roughly equally misreported across the FFQ, 4DFR, and 24HR. All instruments were associated with considerable intake- and person-specific bias. Three 24HRs would provide the least attenuated risk estimate for sugars (attenuation factor, AF = 0.57), followed by FFQ (AF = 0.48) and 4DFR (AF = 0.32), in studies of energy-adjusted sugars and disease risk. In calibration models, self-reports explained little variation in true intake (5%–6% for absolute sugars and 7%–18% for sugars density). Adding participants' characteristics somewhat improved the percentage variation explained (16%–18% for absolute sugars and 29%–40% for sugars density).

Conclusions: None of the self-report instruments provided a good estimate of sugars intake, although overall 24HRs seemed to perform the best.

Impact: Assuming the calibrated sugars biomarker is unbiased, this analysis suggests that measuring the biomarker in a subsample of the study population for calibration purposes may be necessary for obtaining unbiased risk estimates in cancer association studies. Cancer Epidemiol Biomarkers Prev; 23(12); 2874–83. ©2014 AACR.
Data from Improving Power to Detect Changes in Blood miRNA Expression by Accounting for Sources of Variability in Experimental Designs
Authors: Daniels Sarah I. , Sillé Fenna C.M. , Goldbaum Audrey , Yee Brenda , Key Ellen F. , Zhang Luoping , Smith Martyn T. , Thomas Reuben
Published: April 2023

Abstract
Background: Blood miRNAs are a new promising area of disease research, but variability in miRNA measurements may limit detection of true-positive findings. Here, we measured sources of miRNA variability and determine whether repeated measures can improve power to detect fold-change differences between comparison groups.

Methods: Blood from healthy volunteers (N = 12) was collected at three time points. The miRNAs were extracted by a method predetermined to give the highest miRNA yield. Nine different miRNAs were quantified using different qPCR assays and analyzed using mixed models to identify sources of variability. A larger number of miRNAs from a publicly available blood miRNA microarray dataset with repeated measures were used for a bootstrapping procedure to investigate effects of repeated measures on power to detect fold changes in miRNA expression for a theoretical case–control study.

Results: Technical variability in qPCR replicates was identified as a significant source of variability (P < 0.05) for all nine miRNAs tested. Variability was larger in the TaqMan qPCR assays (SD = 0.15–0.61) versus the qScript qPCR assays (SD = 0.08–0.14). Inter- and intraindividual and extraction variability also contributed significantly for two miRNAs. The bootstrapping procedure demonstrated that repeated measures (20%–50% of N) increased detection of a 2-fold change for approximately 10% to 45% more miRNAs.

Conclusion: Statistical power to detect small fold changes in blood miRNAs can be improved by accounting for sources of variability using repeated measures and choosing appropriate methods to minimize variability in miRNA quantification.

Impact: This study demonstrates the importance of including repeated measures in experimental designs for blood miRNA research.

See all the articles in this CEBP Focus section, “Biomarkers, Biospecimens, and New Technologies in Molecular Epidemiology.”

Cancer Epidemiol Biomarkers Prev; 23(12); 2658–66. ©2014 AACR.
Data from Methylation of the Polycomb Group Target Genes Is a Possible Biomarker for Favorable Prognosis in Colorectal Cancer
Authors: Dallol Ashraf , Al-Maghrabi Jaudah , Buhmeida Abdelbaset , Gari Mamdooh A. , Chaudhary Adeel G. , Schulten Hans-Juergen , Abuzenadah Adel M. , Al-Ahwal Mahmoud S. , Sibiany Abdulrahman , Al-Qahtani Mohammed H.
Published: April 2023

Abstract
Background: Colorectal cancer (CRC) is the second most common cancer in the Kingdom of Saudi Arabia with ever increasing incidence rates. DNA methylation is a common event in CRC where it is now considered an important phenomenon in CRC carcinogenesis and useful for the classification and prognosis of CRC.

Methods: To gain insight into the molecular mechanisms underpinning CRC in Saudi Arabian patients, we profiled the DNA methylation frequency of key genes (MLH1, MSH2, RASSF1A, SLIT2, HIC1, MGMT, SFRP1, MYOD1, APC, CDKN2A, as well as five CIMP markers) in 120 sporadic CRC cases. CRC tumors originating from the rectum, left, and right colons are represented in this cohort of formalin-fixed paraffin-embedded tissues.

Results: The most common methylation frequency was detected in the polycomb group target genes (PCGT) including SFRP1 (70%), MYOD1 (60.8%), HIC1 (61.7%), and SLIT2 (56.7%). In addition, MGMT methylation was detected at a high frequency (68.3%). RASSF1A, APC, and CDKN2A methylation frequencies were 42.5%, 25%, and 32.8%, respectively. K-means clustering analysis of the methylation events results in the clustering of the CRC samples into three groups depending on the level of methylation detected.

Conclusion: Group II (PCGT methylation and CIMP-negative) methylation signature carried a favorable prognosis for male patients, whereas older patients with group I rare methylation signature have a potentially poorer clinical outcome.

Impact: Methylation of the PCGT genes along with RASSF1A, APC, and MGMT can be potentially used as a new biomarker for the classification and prognosis of CRC tumors and independently of where the tumor has originated. Cancer Epidemiol Biomarkers Prev; 21(11); 2069–75. ©2012 AACR.
Data from Systematic Review and Meta-study Synthesis of Qualitative Studies Evaluating Facilitators and Barriers to Participation in Colorectal Cancer Screening
Authors: Honein-AbouHaidar Gladys N. , Kastner Monika , Vuong Vincent , Perrier Laure , Daly Corinne , Rabeneck Linda , Straus Sharon , Baxter Nancy N.
Published: April 2023

Abstract
Screening reduces the incidence, morbidity, and mortality of colorectal cancer, yet participation tends to be low. We undertook a systematic review and meta-study synthesis of qualitative studies to identify facilitators and barriers to colorectal cancer screening participation. We searched major bibliographic databases for records published in all languages from inception to February 2015. Included primary studies that elicited views and perceptions towards colorectal cancer screening were appraised for relevance and quality. We used a two-stage synthesis to create an interpretation of colorectal cancer screening decisions grounded in primary studies; a thematic analysis to group themes and systematically compare studies and a meta-synthesis to generate an expanded theory of colorectal cancer screening participation. Ninety-four studies were included. The decision to participate in colorectal cancer screening depended on an individual's awareness of colorectal cancer screening. Awareness affected views of cancer, attitudes towards colorectal cancer screening modalities, and motivation for screening. Factors mediating awareness included public education to address misconceptions, primary care physician efforts to recommend screening, and the influence of friends and family. Specific barriers to participation in populations with lower participation rates included language barriers, logistical challenges to attending screening tests, and cultural beliefs. This study identifies key barriers, facilitators, and mediators to colorectal cancer screening participation. Cancer Epidemiol Biomarkers Prev; 25(6); 907–17. ©2016 AACR.
Data from Serum 25-Hydroxyvitamin D and Cancer Risk in Older Adults: Results from a Large German Prospective Cohort Study
Authors: Ordóñez-Mena José M. , Schöttker Ben , Haug Ulrike , Müller Heiko , Köhrle Josef , Schomburg Lutz , Holleczek Bernd , Brenner Hermann
Published: April 2023

Abstract
Background: Several observational studies assessed the relationship between serum 25-hydroxyvitamin D [25(OH)D] concentrations and the risk of cancer but results were inconclusive.

Methods: We measured 25(OH)D concentrations in a population-based cohort study of 9,949 men and women ages 50 to 74 years in Saarland, Germany. Comprehensively adjusted Cox regression models were applied to estimate HRs and 95% confidence intervals (CI) for the association between season-standardized 25(OH)D concentrations and total and site-specific cancer incidence.

Results: Overall, during a median of 8 years of follow-up, 873 subjects developed cancer; the most common being prostate (171), breast (137), lung (136), and colorectal (136) cancer. Low season-standardized 25(OH)D (<30, 35, 40, or 36 nmol/L in winter, spring, summer, and autumn, respectively) was neither significantly associated with total cancer incidence (HR, 1.10; 95% CI, 0.93–1.30) nor with site-specific cancer incidence. However, a significantly increased overall cancer risk was observed for low 25(OH)D among men, nonobese subjects and subjects reporting low fish consumption and for high 25(OH)D in nonsmokers and nonobese subjects. Accordingly, restricted cubic splines to investigate dose–response relationships curves showed an inverse association of 25(OH)D levels and total cancer risk in men but not in women.

Conclusions: 25(OH)D concentrations were significantly associated with overall cancer incidence in subgroups of this large cohort from Germany. No significant association was observed with site-specific cancers but this could be due to a limited statistical power for these endpoints.

Impact: Further research should clarify whether and to what extent specific risk groups might profit from vitamin D supplementation. Cancer Epidemiol Biomarkers Prev; 22(5); 905–16. ©2013 AACR.
Supplementary Table from Progression and Tumor Heterogeneity Analysis in Early Rectal Cancer
Authors: Lips Esther H. , van Eijk Ronald , de Graaf Eelco J.R. , Doornebosch Pascal G. , de Miranda Noel F.C.C. , Oosting Jan , Karsten Tom , Eilers Paul H.C. , Tollenaar Rob A.E.M. , van Wezel Tom , Morreau Hans
Published: April 2023

Supplementary Table from Progression and Tumor Heterogeneity Analysis in Early Rectal Cancer
Supplementary Data from Impaired STAT Phosphorylation in T Cells from Melanoma Patients in Response to IL-2: Association with Clinical Stage
Authors: Mortarini Roberta , Vegetti Claudia , Molla Alessandra , Arienti Flavio , Ravagnani Fernando , Maurichi Andrea , Patuzzo Roberto , Santinami Mario , Anichini Andrea
Published: April 2023

Supplementary Data from Impaired STAT Phosphorylation in T Cells from Melanoma Patients in Response to IL-2: Association with Clinical Stage
Supplementary Table S2 from Dendritic Cell Vaccination Combined with CTLA4 Blockade in Patients with Metastatic Melanoma
Authors: Ribas Antoni , Comin-Anduix Begoña , Chmielowski Bartosz , Jalil Jason , de la Rocha Pilar , McCannel Tara A. , Ochoa Maria Teresa , Seja Elizabeth , Villanueva Arturo , Oseguera Denise K. , Straatsma Bradley R. , Cochran Alistair J. , Glaspy John A. , Hui Liu , Marincola Francesco M. , Wang Ena , Economou James S. , Gomez-Navarro Jesus
Published: April 2023

Supplementary Table S2 from Dendritic Cell Vaccination Combined with CTLA4 Blockade in Patients with Metastatic Melanoma
Supplementary Figure 1 from Metabolic Imaging: A Link between Lactate Dehydrogenase A, Lactate, and Tumor Phenotype
Authors: Serganova Inna , Rizwan Asif , Ni Xiaohui , Thakur Sunitha B. , Vider Jelena , Russell James , Blasberg Ronald , Koutcher Jason A.
Published: April 2023

PDF file - 442K
Supplementary Tables 1-2 from Autophagy Activation in Hepatocellular Carcinoma Contributes to the Tolerance of Oxaliplatin via Reactive Oxygen Species Modulation
Authors: Ding Zhen-Bin , Hui Bo , Shi Ying-Hong , Zhou Jian , Peng Yuan-Fei , Gu Cheng-Yu , Yang Hua , Shi Guo-Ming , Ke Ai-Wu , Wang Xiao-Ying , Song Kang , Dai Zhi , Shen Ying-Hao , Fan Jia
Published: April 2023

PDF file - 5150K
Supplementary Data 1 from Serum Autoantibody Signature of Ductal Carcinoma In Situ Progression to Invasive Breast Cancer
Authors: Mangé Alain , Lacombe Jérôme , Bascoul-Mollevi Caroline , Jarlier Marta , Lamy Pierre-Jean , Rouanet Philippe , Maudelonde Thierry , Solassol Jérôme
Published: April 2023

PDF file - 303K
Supplementary Figure 1 from Autophagy Activation in Hepatocellular Carcinoma Contributes to the Tolerance of Oxaliplatin via Reactive Oxygen Species Modulation
Authors: Ding Zhen-Bin , Hui Bo , Shi Ying-Hong , Zhou Jian , Peng Yuan-Fei , Gu Cheng-Yu , Yang Hua , Shi Guo-Ming , Ke Ai-Wu , Wang Xiao-Ying , Song Kang , Dai Zhi , Shen Ying-Hao , Fan Jia
Published: April 2023

PDF file - 594K, Analysis of transfection efficiency by fluorescent microscopy.
Supplementary Figure 2 from Infiltration of Lynch Colorectal Cancers by Activated Immune Cells Associates with Early Staging of the Primary Tumor and Absence of Lymph Node Metastases
Authors: de Miranda Noel F.C.C. , Goudkade Danny , Jordanova Ekaterina S. , Tops Carli M.J. , Hes Frederik J. , Vasen Hans F.A. , van Wezel Tom , Morreau Hans
Published: April 2023

PDF file - 183K
Supplementary Data from Phase I and Pharmacokinetic Study of CT-322 (BMS-844203), a Targeted Adnectin Inhibitor of VEGFR-2 Based on a Domain of Human Fibronectin
Authors: Tolcher Anthony W. , Sweeney Christopher J. , Papadopoulos Kyri , Patnaik Amita , Chiorean Elena G. , Mita Alain C. , Sankhala Kamalesh , Furfine Eric , Gokemeijer Jochem , Iacono Lisa , Eaton Cheryl , Silver Bruce A. , Mita Monica
Published: April 2023

Supplementary Figure S1.
Supplementary Methods, Figures 1-2, Figure 4, Tables 1-5 from An Apoptosis Methylation Prognostic Signature for Early Lung Cancer in the IFCT-0002 Trial
Authors: de Fraipont Florence , Levallet Guénaëlle , Creveuil Christian , Bergot Emmanuel , Beau-Faller Michèle , Mounawar Mounia , Richard Nicolas , Antoine Martine , Rouquette Isabelle , Favrot Marie-Christine , Debieuvre Didier , Braun Denis , Westeel Virginie , Quoix Elisabeth , Brambilla Elisabeth , Hainaut Pierre , Moro-Sibilot Denis , Morin Franck , Milleron Bernard , Zalcman Gérard
Published: April 2023

PDF file - 344K, Supplementary methods, suppl. Figure 1 with with the specimens flow-chart, suppl. Figure 2 with the diagram of the clinical trial IFCT 0002 and sampling timepoints, suppl. Figure 4 with RASSF1A interactome, suppl. Table 1 & 2 with primers used in the study, suppl. Table 3 with all the molecular analyses in the bio-IFCT 0002 study, suppl. Table 4 comparing patients with or without molecular analyses, suppl. Table 5 with all the HRs and p-values forthe molecular and clinical variables in the final prognostic analysis
Supplementary Figure 4 from Disruptive TP53 Mutation Is Associated with Aggressive Disease Characteristics in an Orthotopic Murine Model of Oral Tongue Cancer
Authors: Sano Daisuke , Xie Tong-Xin , Ow Thomas J. , Zhao Mei , Pickering Curtis R. , Zhou Ge , Sandulache Vlad C. , Wheeler David A. , Gibbs Richard A. , Caulin Carlos , Myers Jeffrey N.
Published: April 2023

PDF file - 1MB
Supplementary Figure 6 from Overexpression of GOLPH3 Promotes Proliferation and Tumorigenicity in Breast Cancer via Suppression of the FOXO1 Transcription Factor
Authors: Zeng Zhaolei , Lin Huanxin , Zhao Xiaohui , Liu Guanglin , Wang Xi , Xu Ruihua , Chen Kun , Li Jun , Song Libing
Published: April 2023

PDF file - 211K, GOLPH3 specially affects FOXO1 transactivity through modulation of FOXO1 sub-cellular localization
Supplementary Figure 4 from Overexpression of GOLPH3 Promotes Proliferation and Tumorigenicity in Breast Cancer via Suppression of the FOXO1 Transcription Factor
Authors: Zeng Zhaolei , Lin Huanxin , Zhao Xiaohui , Liu Guanglin , Wang Xi , Xu Ruihua , Chen Kun , Li Jun , Song Libing
Published: April 2023

PDF file - 59K, IHC analysis of GOLPH3 and Ki-67 expression in breast cancer tissues
Supplementary Data from C Terminus of Clostridium perfringens Enterotoxin Downregulates CLDN4 and Sensitizes Ovarian Cancer Cells to Taxol and Carboplatin
Authors: Gao Zhijian , Xu Xiaoyin , McClane Bruce , Zeng Qing , Litkouhi Babak , Welch William R. , Berkowitz Ross S. , Mok Samuel C. , Garner Elizabeth I.O.
Published: April 2023

Supplementary Figures S1-S3.
Supplementary Figure 1 from Pretargeted Radioimmunotherapy Using Genetically Engineered Antibody-Streptavidin Fusion Proteins for Treatment of Non-Hodgkin Lymphoma
Authors: Park Steven I. , Shenoi Jaideep , Frayo Shani M. , Hamlin Donald K. , Lin Yukang , Wilbur D. Scott , Stayton Patrick S. , Orgun Nural , Hylarides Mark , Buchegger Franz , Kenoyer Aimee L. , Axtman Amanda , Gopal Ajay K. , Green Damian J. , Pagel John M. , Press Oliver W.
Published: April 2023

PDF file - 112K
Supplementary Table 3 from Methylated RASSF1a Is the First Specific DNA Marker for Minimal Residual Disease Testing in Neuroblastoma
Authors: Stutterheim Janine , Ichou Fatima Ait , den Ouden Emmy , Versteeg Rogier , Caron Huib N. , Tytgat Godelieve A.M. , van der Schoot C. Ellen
Published: April 2023

PDF file - 60K
Supplementary Methods, Table 1 from Early Tumor Progression Associated with Enhanced EGFR Signaling with Bortezomib, Cetuximab, and Radiotherapy for Head and Neck Cancer
Authors: Argiris Athanassios , Duffy Austin G. , Kummar Shivaani , Simone Nicole L. , Arai Yoshio , Kim Seungwon W. , Rudy Susan F. , Kannabiran Vishnu R. , Yang Xinping , Jang Minyoung , Chen Zhong , Suksta Nanette , Cooley-Zgela Theresa , Ramanand Susmita G. , Ahsan Aarif , Nyati Mukesh K. , Wright John J. , Van Waes Carter
Published: April 2023

PDF file - 101K
Supplementary Figure 1a from Methylated RASSF1a Is the First Specific DNA Marker for Minimal Residual Disease Testing in Neuroblastoma
Authors: Stutterheim Janine , Ichou Fatima Ait , den Ouden Emmy , Versteeg Rogier , Caron Huib N. , Tytgat Godelieve A.M. , van der Schoot C. Ellen
Published: April 2023

PDF file - 39K
CCR Translation for This Article from Metformin Use Is Associated with Better Survival of Diabetic Patients with Pancreatic Cancer
Authors: Sadeghi Navid , Abbruzzese James L. , Yeung Sai-Ching J. , Hassan Manal , Li Donghui
Published: April 2023

CCR Translation for This Article from Metformin Use Is Associated with Better Survival of Diabetic Patients with Pancreatic Cancer
Supplementary Figure 4 from Modeling a Lethal Prostate Cancer Variant with Small-Cell Carcinoma Features
Authors: Tzelepi Vassiliki , Zhang Jiexin , Lu Jing-Fang , Kleb Brittany , Wu Guanglin , Wan Xinhai , Hoang Anh , Efstathiou Eleni , Sircar Kanishka , Navone Nora M. , Troncoso Patricia , Liang Shoudan , Logothetis Christopher J. , Maity Sankar N. , Aparicio Ana M.
Published: April 2023

PDF file - 1.1MB, A, Chromosomal regions commonly amplified (red) and deleted (blue) in the SCPC/LCNEC (left panel) and adenocarcinoma (AdCa, right panel) xenografts. B, AR, cyclin D1, and RB1 promoter methylation of the AR-positive LNCaP prostate cancer cell line, the AR-negative PC-3 and DU145 prostate cancer cell lines, and the SCPC/LCNEC MDA PCa 144-4, 144-13, 146-10, and 155-2 xenografts. SCPC, small-cell prostate carcinoma; LCNEC, large-cell neuroendocrine carcinoma; AR, androgen receptor; RB, retinoblastoma.
Supplementary Figures 1-11 from A Comprehensive Analysis of Human Gene Expression Profiles Identifies Stromal Immunoglobulin κ C as a Compatible Prognostic Marker in Human Solid Tumors
Authors: Schmidt Marcus , Hellwig Birte , Hammad Seddik , Othman Amnah , Lohr Miriam , Chen Zonglin , Boehm Daniel , Gebhard Susanne , Petry Ilka , Lebrecht Antje , Cadenas Cristina , Marchan Rosemarie , Stewart Joanna D. , Solbach Christine , Holmberg Lars , Edlund Karolina , Kultima Hanna Göransson , Rody Achim , Berglund Anders , Lambe Mats , Isaksson Anders , Botling Johan , Karn Thomas , Müller Volkmar , Gerhold-Ay Aslihan , Cotarelo Christina , Sebastian Martin , Kronenwett Ralf , Bojar Hans , Lehr Hans-Anton , Sahin Ugur , Koelbl Heinz , Gehrmann Mathias , Micke Patrick , Rahnenführer Jörg , Hengstler Jan G.
Published: April 2023

PDF file - 722K
Supplementary Figure 1 from Omental Adipose Tissue–Derived Stromal Cells Promote Vascularization and Growth of Endometrial Tumors
Authors: Klopp Ann H. , Zhang Yan , Solley Travis , Amaya-Manzanares Felipe , Marini Frank , Andreeff Michael , Debeb Bisrat , Woodward Wendy , Schmandt Rosemarie , Broaddus Russell , Lu Karen , Kolonin Mikhail G.
Published: April 2023

PDF file - 387K, Three-lineage differentiation of O-ASC.
Supplementary Table 1 from Resistance to CYP17A1 Inhibition with Abiraterone in Castration-Resistant Prostate Cancer: Induction of Steroidogenesis and Androgen Receptor Splice Variants
Authors: Mostaghel Elahe A. , Marck Brett T. , Plymate Stephen R. , Vessella Robert L. , Balk Stephen , Matsumoto Alvin M. , Nelson Peter S. , Montgomery R. Bruce
Published: April 2023

PDF file - 20K
Supplementary Figure 2 from Predictive and Prognostic Roles of BRAF Mutation in Stage III Colon Cancer: Results from Intergroup Trial CALGB 89803
Authors: Ogino Shuji , Shima Kaori , Meyerhardt Jeffrey A. , McCleary Nadine J. , Ng Kimmie , Hollis Donna , Saltz Leonard B. , Mayer Robert J. , Schaefer Paul , Whittom Renaud , Hantel Alexander , Benson Al B. , Spiegelman Donna , Goldberg Richard M. , Bertagnolli Monica M. , Fuchs Charles S.
Published: April 2023

PDF file - 50K, aplan-Meier analyses of stage III colon cancer patients according to treatment arm and MSI status. DFS, disease-free survival; FU/LV, 5-fluorouracil and leucovorin; IFL, irinotecan, 5-fluorouracil and leucovorin; MSI, microsatellite instability; MSS, microsatellite stable; OS, overall survival; RFS, recurrence-free survival.
Supplementary Figure 4 from Proximal Tubular Secretion of Creatinine by Organic Cation Transporter OCT2 in Cancer Patients
Authors: Ciarimboli Giuliano , Lancaster Cynthia S. , Schlatter Eberhard , Franke Ryan M. , Sprowl Jason A. , Pavenstädt Hermann , Massmann Vivian , Guckel Denise , Mathijssen Ron H. J. , Yang Wenjian , Pui Ching-Hon , Relling Mary V. , Herrmann Edwin , Sparreboom Alex
Published: April 2023

PDF file - 42K
Supplementary Figure 2 from Proximal Tubular Secretion of Creatinine by Organic Cation Transporter OCT2 in Cancer Patients
Authors: Ciarimboli Giuliano , Lancaster Cynthia S. , Schlatter Eberhard , Franke Ryan M. , Sprowl Jason A. , Pavenstädt Hermann , Massmann Vivian , Guckel Denise , Mathijssen Ron H. J. , Yang Wenjian , Pui Ching-Hon , Relling Mary V. , Herrmann Edwin , Sparreboom Alex
Published: April 2023

PDF file - 29K
Supplementary Table 5B from High ALK Receptor Tyrosine Kinase Expression Supersedes ALK Mutation as a Determining Factor of an Unfavorable Phenotype in Primary Neuroblastoma
Authors: Schulte Johannes H. , Bachmann Hagen S. , Brockmeyer Bent , DePreter Katleen , Oberthür André , Ackermann Sandra , Kahlert Yvonne , Pajtler Kristian , Theissen Jessica , Westermann Frank , Vandesompele Jo , Speleman Frank , Berthold Frank , Eggert Angelika , Brors Benedikt , Hero Barbara , Schramm Alexander , Fischer Matthias
Published: April 2023

XLS file - 2048K
Supplementary Table 3 from Detection of TIMP3 Promoter Hypermethylation in Salivary Rinse as an Independent Predictor of Local Recurrence-Free Survival in Head and Neck Cancer
Authors: Sun Wenyue , Zaboli David , Wang Hao , Liu Yan , Arnaoutakis Demetri , Khan Tanbir , Khan Zubair , Koch Wayne M. , Califano Joseph A.
Published: April 2023

PDF file - 55K, Association of each marker individually with local recurrence-free survival, adjusted for other patient and clinical characteristics of primary tumor site.
Supplementary Data from A Pharmacodynamic Study of Docetaxel in Combination with the P-glycoprotein Antagonist Tariquidar (XR9576) in Patients with Lung, Ovarian, and Cervical Cancer
Authors: Kelly Ronan J. , Draper Deborah , Chen Clara C. , Robey Robert W. , Figg William D. , Piekarz Richard L. , Chen Xiaohong , Gardner Erin R. , Balis Frank M. , Venkatesan Aradhana M. , Steinberg Seth M. , Fojo Tito , Bates Susan E.
Published: April 2023

Supplementary Figures S1-S2; Supplementary Tables S1-S2.
Supplementary Figures 1-3, Tables 1-3 from Functional Analysis of the ATM-p53-p21 Pathway in the LRF CLL4 Trial: Blockade at the Level of p21 Is Associated with Short Response Duration
Authors: Lin Ke , Adamson Janet , Johnson Gillian G. , Carter Anthony , Oates Melanie , Wade Rachel , Richards Sue , Gonzalez David , Matutes Estella , Dearden Claire , Oscier David G. , Catovsky Daniel , Pettitt Andrew R.
Published: April 2023

PDF file - 442K, Functional Analysis of the ATM-p53-p21 pathway in CLL4 trial
Supplementary Methods, Tables 1-5, Figure Legends 1-9 from Quantitative Immunofluorescence Reveals the Signature of Active B-cell Receptor Signaling in Diffuse Large B-cell Lymphoma
Authors: Bogusz Agata M. , Baxter Richard H.G. , Currie Treeve , Sinha Papiya , Sohani Aliyah R. , Kutok Jeffery L. , Rodig Scott J.
Published: April 2023

PDF file - 462K, Table S1: pLYN, pSYK and pBTK levels in DLBCL cell lines; S2 DLBCL cell line classification
Supplementary Figure 1 from 14-3-3ζ, a Novel Androgen-Responsive Gene, Is Upregulated in Prostate Cancer and Promotes Prostate Cancer Cell Proliferation and Survival
Authors: Murata Taro , Takayama Ken-ichi , Urano Tomohiko , Fujimura Tetsuya , Ashikari Daisaku , Obinata Daisuke , Horie-Inoue Kuniko , Takahashi Satoru , Ouchi Yasuyoshi , Homma Yukio , Inoue Satoshi
Published: April 2023

PDF file, 152K, Elevated motility by 14-3-3ζ overexpression in LNCaP cells.
Supplementary Figure 6 from PI3K/mTOR Inhibitor PF-04691502 Antitumor Activity Is Enhanced with Induction of Wild-Type TP53 in Human Xenograft and Murine Knockout Models of Head and Neck Cancer
Authors: Herzog Amanda , Bian Yansong , Vander Broek Robert , Hall Bradford , Coupar Jamie , Cheng Hui , Sowers Anastasia L. , Cook John D. , Mitchell James B. , Chen Zhong , Kulkarni Ashok B. , Van Waes Carter
Published: April 2023

PDF file - 1769K, Effects on weight.
Supplementary Figure 5 from PI3K/mTOR Inhibitor PF-04691502 Antitumor Activity Is Enhanced with Induction of Wild-Type TP53 in Human Xenograft and Murine Knockout Models of Head and Neck Cancer
Authors: Herzog Amanda , Bian Yansong , Vander Broek Robert , Hall Bradford , Coupar Jamie , Cheng Hui , Sowers Anastasia L. , Cook John D. , Mitchell James B. , Chen Zhong , Kulkarni Ashok B. , Van Waes Carter
Published: April 2023

PDF file - 1957K, Treatment in UM-SCC xenograft and Tgfbr1/Pten KO mice.
Supplementary Table 3 from Galectin-1 Promotes Lung Cancer Progression and Chemoresistance by Upregulating p38 MAPK, ERK, and Cyclooxygenase-2
Authors: Chung Ling-Yen , Tang Shye-Jye , Sun Guang-Huan , Chou Teh-Ying , Yeh Tien-Shun , Yu Sung-Liang , Sun Kuang-Hui
Published: April 2023

PDF file, 68KB, Sequences of primer pairs used in reverse transcription polymerase chain reaction (RT-PCR).
Supplementary Figure 1 from PI3K/mTOR Inhibitor PF-04691502 Antitumor Activity Is Enhanced with Induction of Wild-Type TP53 in Human Xenograft and Murine Knockout Models of Head and Neck Cancer
Authors: Herzog Amanda , Bian Yansong , Vander Broek Robert , Hall Bradford , Coupar Jamie , Cheng Hui , Sowers Anastasia L. , Cook John D. , Mitchell James B. , Chen Zhong , Kulkarni Ashok B. , Van Waes Carter
Published: April 2023

PDF file - 3324K, Effects on PI3K-mTOR, TP53 and p73.
Supplementary Figure S4 from The IL-18 Antagonist IL-18–Binding Protein Is Produced in the Human Ovarian Cancer Microenvironment
Authors: Carbotti Grazia , Barisione Gaia , Orengo Anna Maria , Brizzolara Antonella , Airoldi Irma , Bagnoli Marina , Pinciroli Patrizia , Mezzanzanica Delia , Centurioni Maria Grazia , Fabbi Marina , Ferrini Silvano
Published: April 2023

Supplementary Figure S4 - PDF file 640K, Immunochemical analysis of IL-18BP expression in EOC cell lines and xenotransplants. Immunochemistry with an anti-IL-18BP Ab shows virtually no reactivity in EOC cell lines (A upper left panel, B left panel), whereas IL-27-cultured A2774 cells (B middle panel) and areas of orthotopic SKOV3 (A) and A2774 (B right panel) xenotransplants express IL-18BP. The sections were observed with a Nikon Eclipse 80i light microscope equipped with a color camera imaging head, using a 40x objective. Bar=100micron
Supplementary Figure 5 from Sequence Dependence of MEK Inhibitor AZD6244 Combined with Gemcitabine for the Treatment of Biliary Cancer
Authors: Xu Junyao , Knox Jennifer J. , Ibrahimov Emin , Chen Eric , Serra Stefano , Tsao Ming , Cao Pinjiang , Vines Douglass , Green David E. , Metran-Nascente Cristiane , McNamara Mairead G. , Hedley David W.
Published: April 2023

PDF file - 93K, Effect of single drug treatment of AZD6244 or gemcitabine on OCIP55 mice model
Supplementary Methods, Figure Legends 1-5 from Iron Deprivation Suppresses Hepatocellular Carcinoma Growth in Experimental Studies
Authors: Ba Qian , Hao Miao , Huang He , Hou Junmei , Ge Shichao , Zhang Zhuzhen , Yin Jun , Chu Ruiai , Jiang Hualiang , Wang Fudi , Chen Kaixian , Liu Hong , Wang Hui
Published: April 2023

PDF file - 184K
Supplementary Figure 1 from Sequence Dependence of MEK Inhibitor AZD6244 Combined with Gemcitabine for the Treatment of Biliary Cancer
Authors: Xu Junyao , Knox Jennifer J. , Ibrahimov Emin , Chen Eric , Serra Stefano , Tsao Ming , Cao Pinjiang , Vines Douglass , Green David E. , Metran-Nascente Cristiane , McNamara Mairead G. , Hedley David W.
Published: April 2023

PDF file - 99K, Characterization of biliary cancer xenografts
Supplementary Figure 2 from Iron Deprivation Suppresses Hepatocellular Carcinoma Growth in Experimental Studies
Authors: Ba Qian , Hao Miao , Huang He , Hou Junmei , Ge Shichao , Zhang Zhuzhen , Yin Jun , Chu Ruiai , Jiang Hualiang , Wang Fudi , Chen Kaixian , Liu Hong , Wang Hui
Published: April 2023

PDF file - 2.4MB
Supplementary Figure 1 from β-Mannosylceramide Activates Type I Natural Killer T Cells to Induce Tumor Immunity without Inducing Long-Term Functional Anergy
Authors: O'Konek Jessica J. , Kato Shingo , Takao Satomi , Izhak Liat , Xia Zheng , Illarionov Petr , Besra Gurdyal S. , Terabe Masaki , Berzofsky Jay A.
Published: April 2023

PDF file, 680K, Mice were injected i.p. with 2.4, 0.48, 0.24 or 0.048 nmol of a-GalCer or vehicle control. After 1 month, splenocytes were harvested and restimulated in vitro with 100 nM a-GalCer or vehicle. IFN-g in culture supernatants was measured after 48 hours of stimulation. Representatives of at least 2 replicate experiments are shown. Bars represent mean plus-minus SD; *, statistically significantly different from vehicle control stimulation; #, statistically significant from corresponding stimulation in vehicle pretreated group p<0.05.
Supplementary Figure 1 from Gene Expression Signature–Based Prognostic Risk Score in Patients with Primary Central Nervous System Lymphoma
Authors: Kawaguchi Atsushi , Iwadate Yasuo , Komohara Yoshihiro , Sano Masakazu , Kajiwara Koji , Yajima Naoki , Tsuchiya Naoto , Homma Jumpei , Aoki Hiroshi , Kobayashi Tsutomu , Sakai Yuko , Hondoh Hiroaki , Fujii Yukihiko , Kakuma Tatsuyuki , Yamanaka Ryuya
Published: April 2023

PDF file, 116K, Marginal plots for the six genes.
Supplementary Table 3 from Cyclophosphamide Induces a Type I Interferon–Associated Sterile Inflammatory Response Signature in Cancer Patients' Blood Cells: Implications for Cancer Chemoimmunotherapy
Authors: Moschella Federica , Torelli Giovanni Fernando , Valentini Mara , Urbani Francesca , Buccione Carla , Petrucci Maria Teresa , Natalino Fiammetta , Belardelli Filippo , Foà Robin , Proietti Enrico
Published: April 2023

PDF file - 136K, List of the genes down-regulated 1-2 days following CTX treatment.
Supplementary Figure 2 from Overexpression of ZEB2 at the Invasion Front of Colorectal Cancer Is an Independent Prognostic Marker and Regulates Tumor Invasion In Vitro
Authors: Kahlert Christoph , Lahes Saleh , Radhakrishnan Praveen , Dutta Shamik , Mogler Carolin , Herpel Esther , Brand Karsten , Steinert Gunnar , Schneider Martin , Mollenhauer Martin , Reissfelder Christoph , Klupp Fee , Fritzmann Johannes , Wunder Christina , Benner Axel , Kloor Matthias , Huth Cathrin , Contin Pietro , Ulrich Alexis , Koch Moritz , Weitz Jürgen
Published: April 2023

PDF file - 300K
Supplementary Table 1 from EDNRB and DCC Salivary Rinse Hypermethylation Has a Similar Performance as Expert Clinical Examination in Discrimination of Oral Cancer/Dysplasia versus Benign Lesions
Authors: Schussel Juliana , Zhou Xian Chong , Zhang Zhe , Pattani Kavita , Bermudez Francisco , Jean-Charles Germain , McCaffrey Thomas , Padhya Tapan , Phelan Joan , Spivakovsky Silvia , Brait Mariana , Li Ryan , Yoo Bowne Helen , Goldberg Judith D. , Rolnitzky Linda , Robbins Miriam , Kerr A. Ross , Sirois David , Califano Joseph A.
Published: April 2023

Supplementary Table 1 - PDF file 90K, Predictive accuracy of risk classification and markers (n=161)
Supplementary Table 2 from Inhibition of GSK3B Bypass Drug Resistance of p53-Null Colon Carcinomas by Enabling Necroptosis in Response to Chemotherapy
Authors: Grassilli Emanuela , Narloch Robert , Federzoni Elena , Ianzano Leonarda , Pisano Fabio , Giovannoni Roberto , Romano Gabriele , Masiero Laura , Leone Biagio Eugenio , Bonin Serena , Donada Marisa , Stanta Giorgio , Helin Kristian , Lavitrano Marialuisa
Published: April 2023

Supplementary Table 2 - PDF file 70K, Cohort of patients characterization
Supplementary Figure 4 from Inhibition of GSK3B Bypass Drug Resistance of p53-Null Colon Carcinomas by Enabling Necroptosis in Response to Chemotherapy
Authors: Grassilli Emanuela , Narloch Robert , Federzoni Elena , Ianzano Leonarda , Pisano Fabio , Giovannoni Roberto , Romano Gabriele , Masiero Laura , Leone Biagio Eugenio , Bonin Serena , Donada Marisa , Stanta Giorgio , Helin Kristian , Lavitrano Marialuisa
Published: April 2023

Supplementary Figure 4 - PDF file 458K, Caspases are not activated after 5FU treatment in GSK3B-silenced HCT116p53KO
Supplementary Figure 1 from Mutated BCR-ABL Generates Immunogenic T-cell Epitopes in CML Patients
Authors: Cai Ann , Keskin Derin B. , DeLuca David S. , Alonso Anselmo , Zhang Wandi , Zhang Guang Lan , Hammond Naa Norkor , Nardi Valentina , Stone Richard M. , Neuberg Donna , Sidney John , Brusic Vladimir , Wu Catherine J.
Published: April 2023

PDF file, 210K, Forty-five distinct peptides were predicted to bind with IC50< 1000 nM, with 60 peptide-allele combinations.
Supplementary Figure Legend from Denosumab Induces Tumor Reduction and Bone Formation in Patients with Giant-Cell Tumor of Bone
Authors: Branstetter Daniel G. , Nelson Scott D. , Manivel J. Carlos , Blay Jean-Yves , Chawla Sant , Thomas David M. , Jun Susie , Jacobs Ira
Published: April 2023

PDF file, 54KB.
Supplementary Data from Inhibition of GSK3B Bypass Drug Resistance of p53-Null Colon Carcinomas by Enabling Necroptosis in Response to Chemotherapy
Authors: Grassilli Emanuela , Narloch Robert , Federzoni Elena , Ianzano Leonarda , Pisano Fabio , Giovannoni Roberto , Romano Gabriele , Masiero Laura , Leone Biagio Eugenio , Bonin Serena , Donada Marisa , Stanta Giorgio , Helin Kristian , Lavitrano Marialuisa
Published: April 2023

Supplementary Data - PDF file 93K, Supplementary Materials and Methods and Supplementary Legend to Figures
Supplementary Figure 1 from Denosumab Induces Tumor Reduction and Bone Formation in Patients with Giant-Cell Tumor of Bone
Authors: Branstetter Daniel G. , Nelson Scott D. , Manivel J. Carlos , Blay Jean-Yves , Chawla Sant , Thomas David M. , Jun Susie , Jacobs Ira
Published: April 2023

PDF file, 12,208KB; Ki67 Staining (Subject 2). A) Baseline sample: Ki67- positive stromal cells and Ki67-negative tumor giant cells; B) On-study sample: Ki67-positive residual tumor stromal cells and Ki67-negative new woven bone.
Supplementary Tables 1 - 4 from FANCD2 Is a Potential Therapeutic Target and Biomarker in Alveolar Rhabdomyosarcoma Harboring the PAX3–FOXO1 Fusion Gene
Authors: Singh Mamata , Leasure Justin M. , Chronowski Christopher , Geier Brian , Bondra Kathryn , Duan Wenrui , Hensley Lauren A. , Villalona-Calero Miguel , Li Ning , Vergis Anthony M. , Kurmasheva Raushan T. , Shen Changxian , Woods Gary , Sebastian Nikhil , Fabian Denise , Kaplon Rita , Hammond Sue , Palanichamy Kamalakannan , Chakravarti Arnab , Houghton Peter J.
Published: April 2023

PDF file - 149KB, Table 1. Treatment schema. Table 2. Radiation enhancement and calculations. Table 3. Demographics and univariate analysis. Table 4. mTOR associated genes in GESA.
Supplementary Figure Legends from FANCD2 Is a Potential Therapeutic Target and Biomarker in Alveolar Rhabdomyosarcoma Harboring the PAX3–FOXO1 Fusion Gene
Authors: Singh Mamata , Leasure Justin M. , Chronowski Christopher , Geier Brian , Bondra Kathryn , Duan Wenrui , Hensley Lauren A. , Villalona-Calero Miguel , Li Ning , Vergis Anthony M. , Kurmasheva Raushan T. , Shen Changxian , Woods Gary , Sebastian Nikhil , Fabian Denise , Kaplon Rita , Hammond Sue , Palanichamy Kamalakannan , Chakravarti Arnab , Houghton Peter J.
Published: April 2023

PDF file - 64KB
Supplementary Figure 2 from Overexpression of Ecdysoneless in Pancreatic Cancer and Its Role in Oncogenesis by Regulating Glycolysis
Authors: Dey Parama , Rachagani Satyanarayana , Chakraborty Subhankar , Singh Pankaj K. , Zhao Xiangshan , Gurumurthy Channabasavaiah Basavaraju , Anderson Judy M. , Lele Subodh , Hollingsworth Michael A. , Band Vimla , Batra Surinder K.
Published: April 2023

PDF file - 1831K, Variation in GLUT4 expression in Scrambled vs. Ecd KD pancreatic cancer cells. (A) Reduction in GLUT4 protein and mRNA level on Ecd depletion
Supplementary Figure Legends from Concomitant BRAF and PI3K/mTOR Blockade Is Required for Effective Treatment of BRAFV600E Colorectal Cancer
Authors: Coffee Erin M. , Faber Anthony C. , Roper Jatin , Sinnamon Mark J. , Goel Gautam , Keung Lily , Wang Wei Vivian , Vecchione Loredana , de Vriendt Veerle , Weinstein Barbara J. , Bronson Roderick T. , Tejpar Sabine , Xavier Ramnik J. , Engelman Jeffrey A. , Martin Eric S. , Hung Kenneth E.
Published: April 2023

Supplementary Figure Legends PDF file 89K, Supplementary Figure Legends for Supplementary Figure 1 and Supplementary Figure 2